Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 9/20 | 0.69 |
| ▸ | RAB9A | P51151 | 9/20 | 0.69 |
| ▸ | POLB | P06746 | 4/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8118107 | 0.83 | EPHX2 (0.61) | TRPV1NPC1RAB9APOLBEPHX2 | |
| SCHEMBL11555827 | 0.82 | EPHX2 (1.00) | TRPV1NPC1RAB9AEPHX2TDP1 | |
| SCHEMBL17478545 | 0.82 | EPHX2 (0.57) | TRPV1EPHX2EPHX1 | |
| SCHEMBL17478562 | 0.82 | EPHX2 (0.57) | TRPV1EPHX2EPHX1 | |
| SCHEMBL4106288 | 0.82 | NPC1 (1.00) | NPC1RAB9APOLBTDP1MEN1 | |
| SCHEMBL13355321 | 0.82 | NPC1 (0.71) | NPC1RAB9APOLBEPHX2TDP1 | |
| SCHEMBL4117365 | 0.81 | NPC1 (0.69) | NPC1RAB9APOLBTDP1MEN1 | |
| SCHEMBL4110447 | 0.80 | NPC1 (1.00) | NPC1RAB9APOLBTDP1MEN1 | |
| SCHEMBL4115937 | 0.78 | NPC1 (1.00) | NPC1RAB9APOLBTDP1MEN1 | |
| SCHEMBL31054230 | 0.78 | NPC1 (1.00) | NPC1RAB9APOLBTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | TRPV1 169/4885NPC1 927/4885RAB9A 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.